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Julian C. Brandmeier, Kirsti Raiko, Zdeněk Farka,* Riikka Peltomaa, Matthias J. Mickert,
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Sensitive immunoassays are required for troponin, a low-abundance cardiac
biomarker in blood. In contrast to conventional (analog) assays that measure
the integrated signal of thousands of molecules, digital assays are based on
counting individual biomarker molecules. Photon-upconversion nanoparticles
(UCNP) are an excellent nanomaterial for labeling and detecting single
biomarker molecules because their unique anti-Stokes emission avoids
optical interference, and single nanoparticles can be reliably distinguished
from the background signal. Here, the effect of the surface architecture and
size of UCNP labels on the performance of upconversion-linked
immunosorbent assays (ULISA) is critically assessed. The size, brightness,
and surface architecture of UCNP labels are more important for measuring
low troponin concentrations in human plasma than changing from an analog
to a digital detection mode. Both detection modes result approximately in the
same assay sensitivity, reaching a limit of detection (LOD) of 10 pg mL−1 in
plasma, which is in the range of troponin concentrations found in the blood of
healthy individuals.
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1. Introduction
Heart diseases such as acute myocardial
infarction (AMI) are the leading cause of
death worldwide.[1] Since there is only a
limited time available from the onset of
the symptoms to lifesaving treatment, fast
and reliable diagnostic tests are essential.
In healthy individuals, cardiac troponin
(cTn) is located exclusively in myocardial
tissue. Therefore, several clinical tests have
been employed to measure elevated levels
of cTn—the recommended biomarker for
AMI—in blood for the early diagnosis of
AMI.[2] cTn is a heterotrimeric complex
consisting of cTnI, cTnT, and TnC.[3,4] The
subunits cTnI and cTnT exist as unique,
recognizable isoforms only in the heart
muscle (myocardium) and are released into
the blood during AMI.[5,6] Highly sensitive,
precise, and specific troponin tests are
required to discriminate between low cTnI
levels in blood and background noise.[7]
Commercial chemiluminescence, electrochemical, or fluores-
cence assays in clinical use[8] reach limits of detection (LOD) in
the range of 0.08–2.7 pg mL−1.[9] According to the European So-
ciety of Cardiology and the American College of Cardiology, in-
creased cTnI or cTnT levels in blood are defined as the value above
the 99th percentile concentration of a healthy reference popula-
tion, which varies typically between 8.67 and 60.4 pg mL−1.[10,11]
Nevertheless, cTnI is a challenging analyte for immunochem-
ical detection, and quantitative measurements can be influenced
by several factors, such as the availability of epitopes for anti-
body binding. Due to the proteolytic susceptibility of the N- and
C-terminal parts of cTnI,[12] antibodies for cTnI assays are often
selected to recognize epitopes in the stable central part.[13,14] Fur-
thermore, since cTnI in the blood is mainly present as a binary
cTnI–TnC complex,[8] the antibodies should recognize both the
free and complexed forms of cTnI. Moreover, phosphorylation or
blocking of the epitopes by autoantibodies or heterophile anti-
bodies may hinder the antibody recognition.[15] As it is unlikely
that a single antibody pair is not affected by some kind of cTnI
modifications or interferences,[16] many cTnI assays use a com-
bination of two capture or two detection antibodies.[9] Further-
more, troponin assays often suffer not only from a low work-
ing range but also from rather poor precision at concentrations
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Figure 1. ULISA configurations for the detection of cardiac troponin (cTnI). a) SA-PEG-UCNP label: A microtiter well is coated with monoclonal mouse
anti-cTnI antibodies to capture cTnI. The biotinylated anti-cTnI antibody binds to cTnI and forms a sandwich immunocomplex, which is detected using SA-
PEG-UCNP labels. b) mAb-PAA-UCNP label: A microtiter well is coated with streptavidin to immobilize biotinylated anti-cTnI antibodies, which capture
cTnI. Finally, mAb-UCNP conjugates bind to cTnI and form a sandwich immunocomplex.
below the 99th percentile.[17] The choice of signal-generating la-
bels is of a paramount importance to improve the assay reliability
and performance.
Photon-upconversion nanoparticles (UCNP) represent
lanthanide-doped luminescent labels emitting shorter-
wavelength light under near-infrared excitation (anti-Stokes
emission), which strongly reduces background interference
because of autofluorescence and light scattering.[18,19] Due to
these remarkable optical properties, UCNPs are excellent labels
for upconversion-linked immunosorbent assays (ULISA).[20–22]
The hydrophobic layer of oleic acid on pristine UCNPs needs
to be replaced by a hydrophilic coating to render the UCNPs
dispersible in aqueous media and allow further bioconjugation.
Alkyne-poly(ethylene glycol) (PEG) conjugated to neridronate,
a bisphosphonate, has been shown to strongly coordinate to
surface lanthanide ions of UCNPs. The alkyne group reacts
with azide-modified streptavidin via click-chemistry.[23,24] Al-
ternatively, surface coating with hydrophilic poly(acrylic acid)
(PAA) yields water-dispersible nanoparticles with excellent
colloidal stability and high density of surface carboxyl groups for
bioconjugation via EDC/NHS activation.[25]
Furthermore, the absence of optical background interferences
enables the detection and counting of individual UCNP labels
using wide-field optical microscopy.[19,26] This has led to the de-
velopment of single-molecule (digital) immunoassays,[27] as op-
posed to analog immunoassays where the integrated signal gen-
erated by thousands of labels is measured. It is essential that the
UCNP labels have the right size and are bright enough to be reli-
ably detectable (and countable) at the single-nanoparticle level. If
this condition is met, the digital assay is essentially independent
of varying particle brightness, particle aggregation, and the in-
strumental background. With high-affinity detection antibodies,
the LOD is limited by (1) the standard deviation of the nonspecif-
ically bound labels in the control sample without analyte, and (2)
counting statistics, as the precision of the measurement depends
on the number of counted events (Poisson noise).
We previously developed a digital ULISA with PEG-
neridronate-based UCNP labels for the detection of prostate-
specific antigen (PSA).[19,26] The digital readout yielded an LOD
of 0.023 pg mL−1, which was 20-fold more sensitive than the
analog readout. In another study, we applied PAA-coated UCNPs
to the detection of cTnI in the analog mode, which resulted in
an LOD of 0.48 pg mL−1.[28,29] Here, we employ both surface
modification strategies for UCNPs and critically assess the effect
of the UCNP label size on the performance of the analog and
digital immunoassay for cTnI. The schemes of the sandwich
ULISAs using either type of label are shown in Figure 1.
2. Experimental Section
2.1. Chemicals and Reagents
A complete list of chemicals and the preparation of alkyne-
PEG-neridronate (Alkyne-PEG-Ner) and the streptavidin-azide
are provided in the Supporting Information. The cTn I-T-C com-
plex, and monoclonal anti-cTnI-antibody (mAb) clones 19C7cc,
MF4cc, 560cc, and 625cc were purchased from Hytest (Turku,
Finland). The mAbs 560cc and 625cc were biotinylated as de-
scribed in the Supporting Information and mAb 19C7 as pre-
viously published.[30] The recombinant anti-cTnI Fab fragment
9707 was cloned from a hybridoma cell line of Medix Biochemica
(Espoo, Finland) and produced and site-specifically biotinylated
as described previously.[31] Blood for the plasma pool from five
anonymized healthy volunteers was collected in lithium-heparin
vacuum tubes (BD Vacutainer 10 mL, Plymouth, UK). Volun-
teers provided written informed consent regarding the use of col-
lected plasma samples according to the principles expressed in
the Declaration of Helsinki. Plasma was stored at −20 °C, and
the aliquots were freshly thawed and centrifuged for 5 min at
1000 g before each experiment. The STAT troponin I test (Abbot,
Chicago, IL, USA) was used to determine the intrinsic cTnI con-
centration in plasma.
The buffers were prepared using double-distilled water and
filtered through a 0.22-µm membrane (Magna Nylon, GVS,
USA). The buffers for the dilution of reagents included phos-
phate buffer (PB; 50 × 10−3 m NaH2PO4/Na2HPO4, pH 7.4),
phosphate-buffered saline (PBS; PB with 150 × 10−3 m NaCl),
Tris-buffered saline (TBS; 50 × 10−3 m Tris, 150 × 10−3 m
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NaCl, pH 7.5). Coating buffer consisted of 50 × 10−3 m
NaHCO3/Na2CO3, 0.05% NaN3, pH 9.6. Two types of wash-
ing buffers were employed: Kaivogen-washing buffer and Tris-
washing buffer (50 × 10−3 m Tris, 5 × 10−3 m CaCl2, 0.05%
Tween 20, pH 7.5). Several assay buffer combinations were in-
vestigated: (1) SuperBlock buffer (10% SuperBlock in TBS, 1 ×
10−3 m KF, 0.05% Tween 20, 0.05% PEG, and 0.05% NaN3, pH
7.5), (2) SuperBlock buffer with 5 × 10−3 m CaCl2 (SuperBlock-
Ca), (3) Kaivogen assay buffer, (4) modified Kaivogen assay buffer
(assay buffer including 0.05% PAA (MW 1200 Da), 1 × 10−3 m
KF, 0.2% milk powder, 0.08% native mouse IgG, 0.005% dena-
tured mouse IgG, pH 8.0), (5) BSA/BGG buffer (37.5 × 10−3 m
Tris, 513 × 10−3 m NaCl, 5% d-trehalose, 2.5% BSA, 0.06% BGG,
0.04% NaN3, pH 8.6), and (6) BSA/BGG/IgG buffer (37.5 × 10−3
m Tris, 500 × 10−3 m NaCl, 5% d-trehalose, 2.5% BSA, 0.06%
BGG, 0.08% native mouse IgG, 0.005% denatured mouse IgG,
0.2% casein, 37.5 U mL−1 heparin, 0.0375% NaN3, pH 7.75). Cal-
ibrator dilutions were prepared in 7.5% BSA/TSA (50 × 10−3 m
Tris, pH 7.75, 150 × 10−3 m NaCl and 0.05% NaN3, with 7.5%
BSA).
2.2. Preparation of and Characterization of UCNP Labels
2.2.1. SA-PEG-UCNP Conjugates
For the preparation of SA-PEG-UCNP labels, UCNPs
(NaYF4:Yb,Er, 63 nm in diameter) were synthesized as de-
scribed in the Supporting Information. The UCNPs (10 mg,
311 µL) dispersed in cyclohexane were mixed with an equal
volume of 200 × 10−3 m HCl and incubated for 30 min at 38 °C
under shaking and an additional 15 min of sonication to remove
the oleic acid from the UCNP surface and mediate a phase trans-
fer from cyclohexane to water. The lower HCl phase was added
to an excess of acetone and centrifuged (1000 g, 20 min) to pre-
cipitate the UCNPs. The UCNP pellet was redispersed in 500 µL
of water, sonicated for 5 min, and 2 mg of the Alkyne-PEG-Ner
linker dissolved in 500 µL of water were added and incubated
overnight at 38 °C under shaking. The Alkyne-PEG-Ner-UCNP
conjugates were dialyzed for 72 h in a Float-A-Lyzer G2 dialysis
device (100 kDa MW cut-off; Fisher Scientific) at 4 °C against 4 L
of 1 × 10−3 m KF in water, which was exchanged nine times.
For the functionalization with streptavidin, 100 µL of Tris-HCl
(375 × 10−3 m, pH 7.5) and an aqueous solution of sodium ascor-
bate (20 µL, 100 × 10−3 m) were added to 10 mg of Alkyne-PEG-
Ner-UCNPs in 1.4 mL of water. After purging the mixture for
45 min with argon, 100 µL of streptavidin-azide (1 mg mL−1
in water) were added, and the mixture was purged for another
10 min. Adding 10 µL of an aqueous solution of 25 × 10−3 m
CuSO4 initiated the click reaction. The suspension was purged
for 40 min with argon and then dialyzed in a Float-A-Lyzer G2
dialysis device (100 kDa MW cut-off) against 4 L of dialysis buffer
(50 × 10−3 m Tris, 0.05% NaN3, 1 × 10−3 m KF, pH 7.5 at 4 °C for
72 h), which was exchanged nine times.[32]
2.2.2. mAb-PAA-UCNP Conjugates
For the preparation of mAb-PAA-UCNP labels, oleic acid-capped
UCNPs (NaYF4:Yb,Er; 40, 48, 56, 64, and 80 nm in diameter)
were obtained from Kaivogen. The oleic acid was removed and
replaced with PAA in a two-step ligand exchange with NOBF4,
as described previously.[33] The UCNPs (25 mg) dispersed in
cyclohexane were mixed with an equal volume of dimethylfor-
mamide (DMF). The suspension was sonicated for 1 min, added
to 25 mg of NOBF4 and vortexed vigorously. During the following
60 min under shaking (1200 rpm), oleic acid on the nanoparti-
cle surface was replaced by BF4
–, which mediated a phase trans-
fer from cyclohexane to DMF. The UCNP dispersion was split
into two aliquots and the particles were precipitated by adding a
fourfold volume excess of chloroform to the dispersion in DMF.
The UCNPs were washed four times by alternating precipitation
with chloroform and centrifugation (11 000 g, 5 min) followed
by redispersion in 200 µL of DMF. The UCNP pellet was resus-
pended in 150 µL DMF, centrifuged (2500 g, 3 min) to remove
possible larger aggregates, and the supernatant was transferred
to a fresh tube. The yield of UCNPs coated with BF4
– was de-
termined by comparing the luminescence of the solution to that
of 10 mg mL−1 UCNP standard, both diluted 200 times in 10 ×
10−3 m B4Na2O7, pH 8 with 0.1% Tween-20).
The DMF dispersion of BF4
–-coated UCNPs was mixed with a
10% solution of poly(acrylic acid) (PAA, MW 2000) in water (ad-
justed to pH 9 by NaOH) such that a twofold mass excess of
PAA compared to UCNPs was obtained. The mixture was fur-
ther diluted with DMF to yield a PAA concentration of 3.3%
and incubated for 24 h at 60 °C under shaking (1400 rpm). The
PAA-coated UCNPs were washed three times by centrifugation
(20 000 g, 15 min) and resuspended twice in 1 mL of water and
finally in 1 mL of sodium borate buffer (50 × 10−3 m H3BO3 with
NaOH, pH 8.0). This suspension was centrifuged once more at
lower speed (2500 g, 3 min) to sediment possible larger aggre-
gates. The supernatant was carefully collected and stored at room
temperature (RT) until further use.
The conjugation of mAb 625cc and mAb 560cc was adapted
from a previously published protocol[28] and all steps were per-
formed at RT. A dispersion of 250 µL of PAA-coated UCNPs
(2 mg) in 20 × 10−3 m aqueous MES buffer (pH 6.1) was activated
using 20 × 10−3 m EDC and 30 × 10−3 m sulfo-NHS for 45 min
under shaking. The UCNPs were washed by two centrifugation
steps (20 000 g, 7 min), the initial one followed by resuspension
in 335 µL and the second in 210 µL of 20 × 10−3 m MES buffer.
40 µL of mAbs solution in 0.9% NaCl was added to yield a fi-
nal antibody concentration of 0.33 mg mL−1 in a total volume of
250 µL. After 2.5 h under rotation, an aqueous solution of 2 m
2-amino-N,N-dimethylacetamide (ADMA) in water (pH 11) was
added to yield a final ADMA concentration of 50 × 10−3 m. The
mixture was rotated for 30 min to terminate the conjugation re-
action and block the nanoparticle surface. After washing twice by
centrifugation (20 000 g, 10 min) and resuspension in 500 µL of
Tris-buffer (10 × 10−3 m Tris, 0.1% Tween 20, pH 8), the antibody-
conjugated UCNPs (mAb-PAA-UCNPs) were resuspended in 5 ×
10−3 m Tris, pH 8.5, 0.05% Tween 85, 0.5% BSA, 0.05% NaN3, pH
8.5, and stored at 4 °C.
2.2.3. Characterization of UCNP Labels
The UCNPs and their conjugates were characterized using trans-
mission electron microscopy (TEM), dynamic light scattering
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(DLS), and upconversion emission spectroscopy as described in
Figures S1–S3 in the Supporting Information.
2.3. ULISA
2.3.1. SA-PEG-UCNP Labels
A high-binding 96-well microtiter plate (𝜇Clear with 190-𝜇m-
thick bottom foil for microscope detection, Greiner, Austria)
was coated with 60 µL of two monoclonal anti-cTnI antibodies
(19C7cc and MF4cc, each 50 ng/well) in coating buffer overnight
at 4 °C. The following steps were carried out at RT. The plate was
washed twice with 250 µL of Tris-washing buffer and blocked
for 1 h with 175 µL of SuperBlock buffer. After two wash-
ing steps, the cTn I-T-C complex was serially diluted in 60 µL
of either BSA/BGG buffer alone, or 20% human plasma in
BSA/BGG buffer and incubated for 1 h. The microtiter plate was
washed twice and incubated for 1 h with 60 µL of a mixture
containing biotinylated anti-cTnI antibodies (560cc and 625cc;
each 0.5 µg mL−1) in SuperBlock-Ca buffer. After two washing
steps, the plate was incubated with 60 µL of SA-PEG-UCNPs
(6.5 µg mL−1) for 1 h in SuperBlock-Ca buffer. After two wash-
ing steps, the plate was left to dry on air.
2.3.2. mAb-PAA-UCNP Labels
All steps were carried out at RT. The mAb-PAA-UCNP labels were
diluted 30 min before starting the assay in modified Kaivogen as-
say buffer to a final concentration of either 4 µg mL−1 of mAb625-
PAA-UCNP alone, or 2 µg mL−1 of each label in a mixture of
mAb625-PAA-UCNP and mAb560cc-PAA-UCNP.
A high-binding 96-well microtiter plate (𝜇Clear with 190-µm-
thick bottom foil for microscope detection, Greiner) was coated
with streptavidin as described earlier.[34] The plates were first
washed with Kaivogen washing buffer. Then, 50 µL of biotiny-
lated mAb 19C7cc (150 ng/well) and Fab 9707 (50 ng/well) in
Kaivogen assay buffer were added and incubated for 30 min
under shaking. After one washing step, the cTn I-T-C complex
was serially diluted in 50 𝜇L/well in 7.5% BSA/TSA or hu-
man plasma, respectively, followed by further dilution to 20%
in BSA/BGG/IgG buffer, and incubated for 30 min. After one
washing step, the mAb-PAA-UCNP labels prepared prior to the
assay were sonicated 3× for 0.5 s with 100% amplitude using a
VialTweeter (Hielscher Ultrasonics, Teltow, Germany) and added
to the microtiter plate (50 𝜇L/well). After 15 min, the microtiter
plate was washed four times and left to dry on air.
2.4. Signal Acquisition and Statistical Analysis
2.4.1. Analog Readout
A modified upconversion microtiter plate reader (Chameleon,
Hidex, Turku, Finland) equipped with a 980-nm laser excitation
source[35] was used for measuring the integrated emission of Er-
doped UCNPs at 540 nm. (1) In the case of SA-PEG-UCNP labels,
64 points were scanned in each well with a distance of 100 µm
and a signal integration time 1 s. Afterwards, the 16 highest and
16 lowest values were discarded, and the mean value was calcu-
lated, providing the truncated average of the intensity in a single
well. (2) In the case of mAb-PAA-UCNP labels, the bottom sur-
face of the microtiter plate wells was scanned using a 3 × 3 raster
with 1.5 mm step size and an exposure time of 2 s and the av-
erage intensity per well was calculated. The plotted averages and
standard deviations (mean ± SD) were determined from three in-
dependent wells. The data was fitted by a four-parameter logistic
function using the software Origin 2020 (OriginLab, USA). The
LODs were obtained by adding three times the standard devia-
tion of the background to the baseline values of the regression
curve.[26]
2.4.2. Digital Readout
An inverted wide-field epifluorescence microscope (Eclipse Ti,
Nikon, Japan) was connected to a continuous-wave 980-nm laser
diode (4 W, Wavespectrum, China) via a multimode optical
fiber (105 µm fiber core, 0.22 NA, Wavespectrum) and a motor-
ized TIRF/Epifluorescence illuminator unit (Eclipse Ti-E, Nikon,
Japan). The filter cube for the detection of Er3+-doped UCNPs
consisted of a long-pass excitation filter (𝜆cut-on = 830 nm, Schott,
Germany), a dichroic mirror (𝜆cut-on = 875 nm, AHF Analysen-
technik, Germany), and a band-pass filter (𝜆 = 535 ± 70 nm,
OD980 ≈ 6, Chroma, USA). The images were acquired on an sC-
MOS camera (5.5 megapixel, Neo, Andor Technology, UK) and
a 100× objective (1.49 NA, CFI HP Apochromat TIRF, Nikon),
which resulted in a power density of 640 W cm−2.
The dry microtiter plate wells were filled with 80 µL of glycerol
for heat dissipation of the NIR laser beam. The software NIS El-
ements 4.5 (Nikon) was used for the acquisition of 9 wide-field
images per well with an imaging area of 166 × 144 µm2 and ex-
posure times between 10 and 30 s (depending on the size—and
thus brightness—of the UCNPs)[19] and for the counting of indi-
vidual UCNPs. The total number of UCNPs per well (n = 3) was
analyzed using a four-parameter logistic function in Origin 2020.
The LODs were obtained by adding three times the standard de-
viation of the background to the baseline values of the regression
curve.[26]
3. Results and Discussion
3.1. Optimization of Antibody Combination and ULISA
Configuration
cTnI is a very fragile analyte prone to proteolytic degrada-
tion, phosphorylation, or complexing with other proteins and
autoantibodies.[16,36–38] As these factors are not relevant when
cTnI is present in well-defined buffers, it is necessary to as-
sess the detectability of cTnI in its physiological environment,
where many different enzymes, troponins, and other proteins
are present in varying concentrations. Therefore, we prepared a
plasma pool from five healthy volunteers and determined the in-
trinsic cTnI concentration using a commercial test (28.8 pg mL−1)
to distinguish it from spiked troponin concentrations.
The immunoassay performance further depends on the care-
ful selection of antibodies and the assay configuration. We first
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Figure 2. Calibration curves of the analog ULISA using biotinylated
mAb 560cc and SA-PEG-UCNP labels. cTnI was serially diluted in either
BSA/BGG buffer (LOD: 41 pg mL−1; bg: 3000 CPS), or first in 20% plasma
and then in BSA/BGG buffer (LOD: 30 pg mL−1; bg: 2200 CPS). The er-
ror bars show the standard deviation of three replicate measurements
(mean ± SD, n = 3). The hatched lines indicate the LODs.
coated the capture antibodies mAb 19C7cc and MF4cc directly on
the microtiter plate surface (Figure 1a). cTnI was then detected
using biotinylated detection antibodies and SA-PEG-UCNP
labels. When comparing the biotinylated detection antibodies
mAb 560cc, mAb 625cc, and a combination of both, mAb 625cc
alone was sufficient to achieve the highest sensitivity (Figure S4a,
Supporting Information). Figure 2 shows the calibration curves
of cTnI either prepared in BSA/BGG buffer or in 20% plasma
and then diluted in BSA/BGG buffer. The LODs of the assay were
41 pg mL−1 in BSA/BGG buffer (corresponding to 120 pg mL−1
in undiluted sample) and 30 pg mL−1 in 20% human plasma
(corresponding to 80 pg mL−1 in undiluted sample). The only
difference between the calibration curves is the slightly lower
background (bg) signal as a result of blocking effects of serum
proteins, which has a positive effect on the LOD measured in
plasma samples. The assay, however, shows no cross-reactivity
towards other proteins in plasma, which would have increased
the background signal.
In the second assay configuration (Figure 1b), we used strep-
tavidin for coating the microtiter plate surface. Independent of a
partial denaturation during the adsorption-based surface attach-
ment, at least one of the four high-affinity binding sites of strep-
tavidin is usually available for binding of biotin. At the same time,
the streptavidin layer affords the right orientation of the biotiny-
lated antibody. This is especially important for binding of small
biotinylated Fab fragments, which may lose their activity through
denaturation after direct adsorption-based surface attachment. In
this configuration, we employed a combination of biotinylated
Fab 9707 and biotinylated mAb 19C7cc. The smaller size of the
Fab fragment enhanced the epitope availability for the detection
antibody.[12] On the detection side, two types of mAb-PAA-UCNP
labels were compared, one carrying mAb 560cc on the nanopar-
ticle surface and the other mAb 625cc. A combination of both
antibody conjugates was also investigated. The LOD was rather
independent of the label type in the buffer (Figure S4, Supporting
Information), but mAb 625cc-PAA-UCNP resulted in a higher
sensitivity in plasma (data not shown) and thus was used for fur-
ther experiments.
3.2. Effect of UCNP Label Size
The size of the UCNP-based detection label is another important
parameter influencing the immunoassay performance. On the
one hand, the size should be small to (1) obtain stable nanoparti-
cle dispersions, (2) reduce nonspecific binding, and (3) minimize
their influence on the antibody–antigen interaction. On the other
hand, a larger size of UCNPs strongly increases their brightness
such that they can be more easily detected. The brightness is par-
ticularly important for the detection of the labels at the single-
nanoparticle level. Therefore, we conjugated UCNPs of 40, 48,
56, 64, and 80 nm in diameter to mAb 625cc and used them as
labels for the detection of cTnI in buffer (Figure 3a) and in human
plasma (Figure 3b).
While the background signal of mAb-PAA-UCNP labels in
BSA/BGG/IgG buffer was in general lower (<2000 CPS) than for
the SA-PEG-UCNP labels in buffer and only increased slightly
with the label size (see Table 1 for a detailed comparison), the
use of plasma resulted in a ten times higher background signal
when the label size increased from 40 to 80 nm. Also, a com-
parison among the same label sizes showed that the background
was 2–20 times higher in plasma than in the buffer. Therefore,
the higher background signal of larger UCNP labels cannot be
simply explained by a higher brightness of larger UCNPs, but is
rather a consequence of plasma components leading to a higher
level of nonspecific binding of the larger particles to the mi-
crotiter plate. The higher LOD of the ULISA with larger UCNP la-
bels in plasma can be attributed to the higher background signal.
The origin of the increased tendency to nonspecific binding of the
larger UCNPs may be related to the larger contact area (affected
also by the shape of the nanoparticles) with the surface, which
may lead a larger number of simultaneous weak interactions.
3.3. Performance of Digital Assays
In our previous work on PSA,[26] we observed that counting sin-
gle immunocomplexes (digital mode, LOD: 0.02 pg mL−1) re-
sulted in a 20-fold higher sensitivity than the analog mode (LOD:
0.4 pg mL−1) using SA-PEG-UCNP detection labels in the same
configuration as shown in Figure 1a. We explained the higher
sensitivity of the digital mode by the reduced influence of la-
bel aggregation in the digital mode, where each aggregate—
independent of its size—is counted only as a single binding
event. In the analog mode, by contrast, an aggregate bound non-
specifically to the microtiter plate surface can strongly increase
the background signal depending on the number of UCNPs in
the aggregate.
In our current work, the same microtiter plates prepared for
the analog detection of troponin were used for counting individ-
ual cTnI immunocomplexes under the upconversion microscope
to determine the concentration in the digital mode. Figure 4
shows microscope images of single immune complexes labeled
with mAb-PAA-UCNPs (56 nm; images of other mAb-PAA-
UCNP sizes and SA-PEG-UCNPs are shown in Figures S5 and
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Figure 3. Analog ULISA for the detection of cTnI using different sizes of UCNP-PAA conjugated to mAb 625cc in a) buffer and b) 20% plasma. The error
bars show standard deviations of replicate measurements in three wells (mean ± SD, n = 3).
Table 1. Summary of the analog and digital detection of cTnI in buffer and in human plasma using mAb-PAA-UCNP labels.
Detection of cTnI in buffer in plasma





























48 1055 3.8 33 3.3 2622 8.6 105 9.8
56 1038 8.3 21 7.0 2958 11.8 74 65.2
64 1129 13.3 15 17.4 11 211 57.2 209 17.2
80 1517 2.9 15 4.7 12 716 44.9 153 160.0
a)
Average UCNP diameter determined by TEM (Figure S1, Supporting Information);
b)
Number of luminescent spots in the background images (0.2 mm2). Average of 3 wells
calculated from the sum of 9 images per well;
c)
Not determinable because smaller UCNPs are not bright enough for single-nanoparticle detection.
S6 in the Supporting Information). A minimal size of 48 nm was
required for a reliable detection at the single-nanoparticle level.
In both buffer and plasma, the distribution of the label bright-
ness was relatively uniform among different types and sizes of
labels (Table S1, Supporting Information), indicating that the
number of aggregates present in the label samples was relatively
small.
The calibration curves of the digital assays are summarized in
Figure 5. In contrast to the analog readout (Figure 3), the number
of nonspecifically bound labels was relatively independent of
the label size in BSA/BGG/IgG buffer and in plasma (Figure 5,
Table 1). While most of the increased background is a result of
more nonspecific binding events in plasma, it should be noted
that in the case of small nanoparticles, also the average bright-
ness per diffraction-limited spot increased, which indicates
that the plasma has an indirect effect on the label aggregation
(Table S1, Supporting Information). As the background mainly
determines the assay sensitivity, the sensitivity of the digital de-
tection in buffer was relatively similar among the different label
sizes. By contrast, the assay sensitivity decreased in plasma when
using larger labels, with exception of the 64-nm conjugates.
We also compared the assay performance in the digital mode
using SA-PEG-UCNP labels (Figure S7, Supporting Informa-
tion), but these labels did not improve the LOD compared to
the analog readout (Figure 2), either. Therefore, independent
of the assay configuration and the type and size of the label,
the analog and digital readout resulted in similar LODs. The
number of nonspecifically bound mAb-PAA-UCNP labels in
the background image of the blank sample (Figure 5a) was
about ten times lower than the number of nonspecifically bound
SA-PEG-UCNP labels (Figure S7, Supporting Information),
which was consistent with our earlier PSA experiments using
SA-PEG-UCNP labels.[26] The lower number of counting events
(n) increased the Poisson noise (
√
n∕n) and affected the accuracy
of the digital readout. For example, in the case of 64-nm UCNPs
and 80-nm UCNP, the nonspecific binding was so low that only
15 diffraction-limited spots were detectable in the imaging area.
A count of 15, however, results in a relatively high Poisson noise
of 26%. In Figure 5a, the lowest baselines show the highest
fluctuations, due to the Poisson noise.
An explanation why the digital readout improved the LOD of
the PSA assay but not the LOD of the troponin assay may be that
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Figure 4. Digital ULISA for the detection of troponin using mAb-PAA-UCNP labels (56 nm in diameter). a–c) Wide-field upconversion microscopy
images corresponding to serial dilutions of cTnI in BSA/BGG/IgG buffer. d) Brightness distribution histogram of 500 diffraction-limited spots recorded
at 50 ng mL−1 of cTnI. e–g) Wide-field upconversion microscopy images corresponding to serial cTnI dilutions in plasma. d) Brightness distribution
histogram of 500 diffraction-limited spots recorded at 50 ng mL−1 of cTnI in plasma. Scale bar: 10 µm.
Figure 5. Digital ULISA for the detection of troponin using different sizes of mAb 625cc-PAA-UCNP labels in a) BSA/BGG/IgG buffer and b) 20% plasma.
The error bars show the standard deviation of replicate measurements in three wells (mean ± SD, n = 3).
the label preparation was more uniform than in our previous PSA
assay. Also, the differences in the particular antibody–antigen in-
teractions may explain why the digital assay confers a higher sen-
sitivity only for some analytes. In the analog mode, the PSA assay
was ten times more sensitive than the troponin assay. In the dig-
ital mode, the PSA assay was even 200 times more sensitive al-
though the number of nonspecifically bound SA-PEG-UCNP la-
bels was ten times higher than the number of mAb-PAA-UCNP
labels. Therefore, it seems to be the first requirement that the
affinity of the antibody for the analyte is already very high be-
fore the sensitivity can be further improved by the digital read-
out. Compared to commercial cTnI assays and literature reports,
however, the ULISA results in a similar or even better assay per-
formance (Table 2).
4. Conclusions
For the detection of troponin (cTnI), the advantages conferred
by optimizing the assay configuration and the size, brightness,
and surface chemistry of UCNP labels were more important than
changing from an analog to a digital detection mode. In both
cases, an LOD of 10 pg mL−1 in human plasma was obtained
using mAb-PAA-UCNPs (48 nm in diameter). In contrast to
conventional analog measurements, the digital readout allowed
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Table 2. Assay platforms for the detection of cTnI.
Detection label LOD [pg mL−1] linear range [ng mL−1] Company/reference
Commercial assays Alkaline phosphatase 20 0.00–50.0 Abbott i-STAT[39]
Alkaline phosphatase 10 0.01–100 Beckman Access 2[40]
Alkaline phosphatase 10 Beckman Coulter DxI[41]
Alkaline phosphatase 2.5 0.0023–27000 Beckman Coulter Access hs-cTnI[42]
Horseradish peroxidase 12 Ortho-Clinical Diagnostics Vitros[43]
Horseradish peroxidase 100 0.125–8.0 Invitrogen: Human Troponin I (TNNI3) ELISA[44]
Literature reports 5′-6-FAM-modified aptamer 70 0.1–6.0 [45]
SERS using graphene oxide/gold NP 5 0.01–1000 [46]
Cyclovoltammetry using whiskered nanofibers 40 0.5–100 [47]
48-nm UCNP (analog/digital readout) 10 0.04–38 (analog readout) This work
for distinguishing between the number of nonspecific binding
events (observable as the number of diffraction-limited spots)
and the degree of label aggregation (observable as an increase
in the brightness of individual diffraction-limited spots). In par-
ticular, measurements in human plasma were strongly affected
by the size of the UCNP labels. While the number of nonspecific
binding events strongly increased with the label size, smaller la-
bels led to slightly more aggregated UCNPs. The digital readout
also showed that a low background signal is important to achieve
a high sensitivity, but ultimately, the digital assay is limited by
the counting noise. When comparing different analytes (troponin
and PSA) measured under similar experimental conditions, the
particular antibody–analyte interaction had a stronger effect on
the assay sensitivity than the degree of nonspecific binding.
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